Prosecutors and a media coalition are challenging the defense's push to seal court documents in the high-profile case against accused assassin Tyler Robinson, igniting a fierce debate over public access and a fair trial.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
The trial of four men charged with the murder of Michelle Sadio, a mother of two killed outside a Harlesden church in 2024, has begun, revealing allegations of a botched attack targeting a local rapper.
The trial of Marius Borg Høiby, son of Crown Princess Mette-Marit, opens in Oslo, exposing a profound crisis for the Norwegian monarchy as he faces charges including rape and assault.
Podcaster Joe Rogan and Senator Bernie Sanders dissect the stark decline of Detroit's auto industry on a recent episode, highlighting abandoned factories, job offshoring, and a city where homes can sell for pennies. The conversation underscores the human cost of deindustrialization and the fierce global competition now facing American automakers.
The Norwegian monarchy is rocked by dual crises as Marius Borg Høiby, son of Crown Princess Mette-Marit, stands trial on serious criminal charges, while newly unsealed Jeffrey Epstein documents reveal extensive past connections to the princess.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Marius Borg Høiby, the eldest son of Crown Princess Mette-Marit, was taken into custody on fresh allegations of assault and weapons offenses just days before his high-profile trial on multiple rape charges is set to begin, deepening the crisis for Norway's monarchy.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
While the industrial sector has surged ahead of the broader market, not all companies are equally positioned for sustainable growth. We analyze one defense contractor with strong tailwinds and two manufacturers where valuation concerns loom large.
While many chase high-risk, loss-making stories, Tyler Technologies (TYL) stands out with consistent profitability and growth. We examine the key metrics and management alignment that make this software provider a stock worth watching.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
While the industrial sector has surged ahead of the broader market, not all companies are positioned to weather an economic downturn. We examine three industrial stocks where valuation and business model concerns suggest investors should proceed with caution.
While often operating behind the scenes, industrial companies are the engine of the U.S. economy. Bolstered by a favorable interest rate environment, the sector has surged 18.8% in the last six months, significantly outpacing the S&P 500. We analyze two firms with durable competitive edges and one that may be losing momentum.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Aalberts N.V. (AMS:AALB), a mid-cap specialist in industrial technology, has seen a significant price surge on the ENXTAM, prompting analysts to revisit its valuation and growth trajectory amidst market volatility.
A consortium of nine major corporations, including Google and Singapore Airlines, is launching a voluntary trial for centralized sustainable aviation fuel (SAF) procurement. This pilot, led by the newly formed SAFCo, is a critical step ahead of Singapore's pioneering green levy on departing flights set for October, aiming to refine systems for a 1% SAF usage target.
